immunoglobulin heavy joining 3P (pseudogene)Genealiases: []
Q-omics provides the consensus-scored IGHJ3P profile across patient tissues and cancer cell-line models. IGHJ3P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGHJ3P is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, IGHJ3P RNA expression shows 14,268 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, COAD, and DLBC as cancer lineages where IGHJ3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHJ3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHJ3P survival associations across molecular data types. IGHJ3P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHJ3P RNA expression–survival associations across cancer types. High IGHJ3P expression shows favorable associations in HNSC, SKCM, OV, LUAD, UCS and SARC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGHJ3P RNA expression.
This table summarizes IGHJ3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGHJ3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHJ3P shows lower tumor expression in COAD, BRCA and READ and higher tumor expression in LUAD, KIRC and THCA. The COAD box plot shows higher IGHJ3P RNA expression in normal versus tumor tissue (log2 FC = −2.819, t-test p < 0.001).
This table shows molecular features associated with IGHJ3P in patient tissues and cancer cell lines. In patient samples, IGHJ3P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
